Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On February 10, 2025, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, had 2,143 shares withheld to cover taxes at a price of $467.98.
• On February 11, 2025, Ms. Tatsis sold 310 shares of Vertex Pharmaceuticals common stock at a price of $459.83.
• These transactions were executed under a company-approved trading plan pursuant to Rule 10b5-1, which was established on February 29, 2024.
• Following these transactions, Ms. Tatsis directly owns 64,021 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive stock sales are common across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also see regular Form 4 filings from their executives.
• The use of 10b5-1 trading plans is a standard practice to avoid accusations of insider trading, allowing executives to sell shares at predetermined times and prices.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased selling pressure.
• The impact on employees, customers, suppliers, and creditors is expected to be negligible.

Key Dates